Find your next paid study

AstraZenecaNCT07291037

Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more

A Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients With Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug d…

Cogent Biosciences, Inc.NCT07361562

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung …

TRIANA Biomedicines, Inc.NCT07491497

Non-small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNSCLC+3 more

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in comb…

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06343402

Advanced Solid TumorMetastatic Solid TumorHead and Neck Squamous Cell Carcinoma+6 more

A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced…

Non-small Cell Lung CancerNSCLC

InduPro, Inc.NCT07602842

Phase 3

Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without mainte…

Merck Sharp & Dohme LLCNCT06422143

Observational

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereota…

Invasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma Stage IVLobular Breast Carcinoma+12 more

Memorial Sloan Kettering Cancer CenterNCT05837767

~$10 – $6,250

Solid Tumor, AdultNon-small Cell Lung CancerMelanoma

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated…

Pierre Fabre MedicamentNCT04913285

Non-Small Cell Lung CancerColorectal CancerBreast Cancer+3 more

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and to…

Fate TherapeuticsNCT07216105

MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath Tumors+3 more

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable…

Bristol-Myers SquibbNCT05245500

Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor …

Pierre Fabre MedicamentNCT06043817

Non Small Cell Lung Cancer

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligan…